Last updated on November 2019

Safety and Efficacy of IMCgp100 Versus Investigator Choice in Advanced Uveal Melanoma

Brief description of study

To evaluate the overall survival of HLA-A*0201 positive adult patients with previously untreated advanced UM receiving IMCgp100 compared to Investigator's Choice of dacarbazine, ipilimumab, or pembrolizumab.

Detailed Study Description

This Phase II study is designed to evaluate the safety and efficacy of IMCgp100 compared with Investigator's Choice (dacarbazine, ipilimumab or pembrolizumab) in HLA-A*0201 positive adult patients with advanced UM treated in the first line setting with no prior systemic or liver-directed chemo-, radio- or immune-therapy administered in the advanced setting (prior surgical resection of liver metastases and adjuvant systemic therapy are acceptable). Comparison of the IMCgp100 efficacy results in this Phase II study will be made with the concurrently randomized arm (Investigator's Choice) with a primary endpoint of overall survival (OS) and secondary efficacy endpoints of progression-free survival (PFS), objective response rate (ORR), duration of response (DOR), and disease control rate (DCR).

Clinical Study Identifier: NCT03070392

Find a site near you

Start Over

UCLA Medical Center

Los Angeles, CA United States
  Connect »

California Pacific Medical Center

San Francisco, CA United States
  Connect »

University of Colorado

Aurora, CO United States
  Connect »

Mount Sinai Medical Center

Miami Beach, FL United States
  Connect »

Northwestern University

Chicago, IL United States
  Connect »

University of Iowa

Iowa City, IA United States
  Connect »

The Ohio State University

Columbus, OH United States
  Connect »

Saint Vincents Hospital

Darlinghurst, Australia
  Connect »

Mount Vernon Cancer Centre

Northwood, United Kingdom
  Connect »

University of Oklahoma

Oklahoma City, OK United States
  Connect »